Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Metabolic findings from the CATIE trial and their relation to tolerability.

Nasrallah HA.

CNS Spectr. 2006 Jul;11(7 Suppl 7):32-9.

PMID:
16816798
2.

Understanding the results of CATIE in the context of the field.

Glick ID.

CNS Spectr. 2006 Jul;11(7 Suppl 7):40-7.

PMID:
16816799
3.

Implications of the CATIE trial on treatment: extrapyramidal symptoms.

Casey DE.

CNS Spectr. 2006 Jul;11(7 Suppl 7):25-31.

PMID:
16816797
5.

Interpreting the efficacy findings in the CATIE study: what clinicians should know.

Meltzer HY, Bobo WV.

CNS Spectr. 2006 Jul;11(7 Suppl 7):14-24.

PMID:
16816796
6.

Antipsychotics and metabolics in the post-CATIE era.

Meyer JM.

Curr Top Behav Neurosci. 2010;4:23-42. Review.

PMID:
21312396
7.

Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study.

Glazer WM, Conley RR, Citrome L.

CNS Spectr. 2006 Sep;11(9 Suppl 10):1-13; quiz 14.

PMID:
16946697
8.
9.

The CATIE schizophrenia trial: results, impact, controversy.

Manschreck TC, Boshes RA.

Harv Rev Psychiatry. 2007 Sep-Oct;15(5):245-58. Review.

PMID:
17924259
10.
11.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
12.
13.

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA.

Schizophr Bull. 2003;29(1):15-31.

PMID:
12908658
14.

The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.

Thomas P.

Eur Neuropsychopharmacol. 2007 Mar;17 Suppl 2:S115-22. Review.

PMID:
17336766
15.

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.

J Ment Health Policy Econ. 2008 Jun;11(2):89-97.

PMID:
18509216
16.

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

Greenberg WM, Citrome L.

CNS Drug Rev. 2007 Summer;13(2):137-77. Review.

17.

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.

Edwards NC, Pesa J, Meletiche DM, Engelhart L, Thompson AK, Sherr J, Dirani R.

Curr Med Res Opin. 2008 Dec;24(12):3341-55. doi: 10.1185/03007990802490512 . Review.

PMID:
18954497
18.

Management of schizophrenia with obesity, metabolic, and endocrinological disorders.

Monteleone P, Martiadis V, Maj M.

Psychiatr Clin North Am. 2009 Dec;32(4):775-94. doi: 10.1016/j.psc.2009.08.003. Review.

PMID:
19944883
19.

Antipsychotic safety and efficacy concerns.

Meyer JM.

J Clin Psychiatry. 2007;68 Suppl 14:20-6. Review.

20.

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.

Nasrallah HA, Newcomer JW.

J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S7-14.

PMID:
15356415

Supplemental Content

Support Center